These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
228 related articles for article (PubMed ID: 36189319)
1. Landscape of prognosis and immunotherapy responsiveness under tumor glycosylation-related lncRNA patterns in breast cancer. Lv W; Tan Y; Zhou X; Zhang Q; Zhang J; Wu Y Front Immunol; 2022; 13():989928. PubMed ID: 36189319 [TBL] [Abstract][Full Text] [Related]
2. Analysis of Tumor Glycosylation Characteristics and Implications for Immune Checkpoint Inhibitor's Efficacy for Breast Cancer. Lv W; Yu H; Han M; Tan Y; Wu M; Zhang J; Wu Y; Zhang Q Front Immunol; 2022; 13():830158. PubMed ID: 35444644 [TBL] [Abstract][Full Text] [Related]
3. Oncogenic signaling pathway-related long non-coding RNAs for predicting prognosis and immunotherapy response in breast cancer. Li H; Liu H; Hao Q; Liu X; Yao Y; Cao M Front Immunol; 2022; 13():891175. PubMed ID: 35990668 [TBL] [Abstract][Full Text] [Related]
4. Computational construction of TME-related lncRNAs signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma. Zhou L; Fang H; Guo F; Yin M; Long H; Weng G J Clin Lab Anal; 2022 Aug; 36(8):e24582. PubMed ID: 35808868 [TBL] [Abstract][Full Text] [Related]
5. Construction and validation of a transient receptor potential-related long noncoding RNA signature for prognosis prediction in breast cancer patients. Guo Q; Qiu P; Pan K; Chen J; Wang B; Lin J Medicine (Baltimore); 2023 Nov; 102(46):e35978. PubMed ID: 37986367 [TBL] [Abstract][Full Text] [Related]
6. An exosome-related long non-coding RNAs risk model could predict survival outcomes in patients with breast cancer. Qiu P; Guo Q; Lin J; Pan K; Chen J; Ding M Sci Rep; 2022 Dec; 12(1):22322. PubMed ID: 36566321 [TBL] [Abstract][Full Text] [Related]
7. Identification of cuproptosis-related long noncoding RNA signature for predicting prognosis and immunotherapy response in bladder cancer. Huang G; Huang Y; Zhang C; Jiang Y; Ye Z; He C; Yu F; Chen Z; Xi X Sci Rep; 2022 Dec; 12(1):21386. PubMed ID: 36496537 [TBL] [Abstract][Full Text] [Related]
8. Necroptosis-related lncRNA to establish novel prognostic signature and predict the immunotherapy response in breast cancer. Chen F; Yang J; Fang M; Wu Y; Su D; Sheng Y J Clin Lab Anal; 2022 Apr; 36(4):e24302. PubMed ID: 35229919 [TBL] [Abstract][Full Text] [Related]
9. A genomic instability-related lncRNA model for predicting prognosis and immune checkpoint inhibitor efficacy in breast cancer. Jiao Y; Li S; Wang X; Yi M; Wei H; Rong S; Zheng K; Zhang L Front Immunol; 2022; 13():929846. PubMed ID: 35990656 [TBL] [Abstract][Full Text] [Related]
10. A new risk model based on a 11-m Lei L; Li N; Yuan P; Liu D BMC Cancer; 2022 Apr; 22(1):365. PubMed ID: 35382776 [TBL] [Abstract][Full Text] [Related]
11. Predicting the immune landscape of invasive breast carcinoma based on the novel signature of immune-related lncRNA. Shen S; Chen X; Hu X; Huo J; Luo L; Zhou X Cancer Med; 2021 Sep; 10(18):6561-6575. PubMed ID: 34378851 [TBL] [Abstract][Full Text] [Related]
12. Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer. Jiang J; Jin Z; Zhang Y; Peng L; Zhang Y; Zhu Z; Wang Y; Tong D; Yang Y; Wang J; Yang Y; Xiao K Front Immunol; 2021; 12():646874. PubMed ID: 33927719 [TBL] [Abstract][Full Text] [Related]
13. Systematic analysis of lncRNA-miRNA-mRNA competing endogenous RNA network identifies four-lncRNA signature as a prognostic biomarker for breast cancer. Fan CN; Ma L; Liu N J Transl Med; 2018 Sep; 16(1):264. PubMed ID: 30261893 [TBL] [Abstract][Full Text] [Related]
14. Comprehensive analysis of tumor immune microenvironment and prognosis of m6A-related lncRNAs in gastric cancer. Wang Y; Zhu GQ; Tian D; Zhou CW; Li N; Feng Y; Zeng MS BMC Cancer; 2022 Mar; 22(1):316. PubMed ID: 35331183 [TBL] [Abstract][Full Text] [Related]
15. MIR155HG is a prognostic biomarker and associated with immune infiltration and immune checkpoint molecules expression in multiple cancers. Peng L; Chen Z; Chen Y; Wang X; Tang N Cancer Med; 2019 Dec; 8(17):7161-7173. PubMed ID: 31568700 [TBL] [Abstract][Full Text] [Related]
16. Immune-related long noncoding RNA signature for predicting survival and immune checkpoint blockade in hepatocellular carcinoma. Zhang Y; Zhang L; Xu Y; Wu X; Zhou Y; Mo J J Cell Physiol; 2020 Dec; 235(12):9304-9316. PubMed ID: 32330311 [TBL] [Abstract][Full Text] [Related]
17. Emerging glyco-risk prediction model to forecast response to immune checkpoint inhibitors in colorectal cancer. Qiu P; Chen X; Xiao C; Zhang M; Wang H; Wang C; Li D; Liu J; Chen Y; Liu L; Zhao Q J Cancer Res Clin Oncol; 2023 Aug; 149(9):6411-6434. PubMed ID: 36757621 [TBL] [Abstract][Full Text] [Related]
18. Identification of immunotherapy-related lncRNA signature for predicting prognosis, immunotherapy responses and drug candidates in bladder cancer. Hui P; Ni F; Zheng L; Jia L; Wang Z BMC Cancer; 2023 Apr; 23(1):355. PubMed ID: 37072750 [TBL] [Abstract][Full Text] [Related]
19. Multi-Omics Perspective Reveals the Different Patterns of Tumor Immune Microenvironment Based on Programmed Death Ligand 1 (PD-L1) Expression and Predictor of Responses to Immune Checkpoint Blockade across Pan-Cancer. Huang K; Hu M; Chen J; Wei J; Qin J; Lin S; Du H Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34068143 [TBL] [Abstract][Full Text] [Related]
20. Prognostic model based on m6A-associated lncRNAs in esophageal cancer. Wang W; Dong D; Yu P; Chen T; Gao R; Wei J; Mo Z; Zhou H; Yang Q; Yue C; Yang X; Li X; Ji G Front Endocrinol (Lausanne); 2022; 13():947708. PubMed ID: 36111294 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]